Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Prescription DrugsPain Management

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1354659

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1354659

Analgesics

PUBLISHED:
PAGES: 578 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

What`s New?

» Special discussions on the global economic climate and market sentiment

» Coverage on global competitiveness and key competitor percentage market shares

» Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial

» Online interactive peer-to-peer collaborative bespoke updates

» Access to our digital archives and MarketGlass™ research platform

» Complimentary updates for one year

» Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes

Economic Outlook

The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US$6 trillion economy by 2030, surpassing Japan and Germany.

The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Analgesics Market to Reach $72.8 Billion by 2030

The global market for Analgesics estimated at US$48.8 Billion in the year 2022, is projected to reach a revised size of US$72.8 Billion by 2030, growing at a CAGR of 5.1% over the period 2022-2030. Prescription, one of the segments analyzed in the report, is projected to record 4.8% CAGR and reach US$43.8 Billion by the end of the analysis period. Growth in the OTC segment is estimated at 5.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $15.9 Billion, While China is Forecast to Grow at 6.9% CAGR

The Analgesics market in the U.S. is estimated at US$15.9 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$10.8 Billion by the year 2030 trailing a CAGR of 6.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.7% and 4.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Select Competitors (Total 146 Featured) -

  • Bristol-Myers Squibb Company
  • Bayer AG
  • Biological E. Ltd.
  • Anabolic Laboratories LLC
  • BioDelivery Sciences International, Inc.
  • Brawn Laboratories Ltd.
  • Angelini Holding S.p.A.
  • AFT Pharmaceuticals Limited
  • APT Asia Pacific
  • Church & Dwight (Australia) Pty Ltd.
  • Alliance Design and Development Group, Inc.
  • Active Releaf Wellness Inc.
  • Abiogen Pharma S.p.A.
  • B-New Limited
  • Celgene Corporation
Show more
Product Code: MCP-5064

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Analgesics - Global Key Competitors Percentage Market Share in 2021 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2021 (E)
    • Impact of Covid-19 and a Looming Global Recession
    • A Prelude to Analgesics
    • Analgesics: Perfect Therapeutic Options to Solve Mild to Crippling Pain
    • Key Segments
    • Opioid Analgesics
    • Non-Opioid Analgesics
    • NSAIDs
    • Topical NSAIDs
    • Others
    • Acetaminophen
    • Adjuvant Analgesics
    • Impact of COVID-19 on Analgesics
    • NSAIDs
    • NSAIDs Tend to Decrease Effectiveness of COVID-19 Vaccines, States a Yale University Study
    • Opioid
    • Acetaminophen
    • Global Analgesics Market to Witness Rapid Growth
    • Drugs Indicated for Pain Management
    • The US and Europe Represent the Largest Regions, Asia-Pacific to Witness fastest Growth
    • Non-Opioids: Fastest Growing Category
    • Competition
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Aging Population & Increasing Burden of Chronic Diseases Spurs
    • Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Rising Diabetes Prevalence Presents Opportunity for Cell Surface Markers: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
    • Growing Incidence of Cancer and the Associated Pain to Drive the Analgesics Market
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
    • Number of New Cancer Cases and Deaths (in Million) by Region for 2018
    • Advancements in Design and Delivery of Analgesic Drugs
    • Development of Safer Opioids with More Safer Profiles
    • Drug Pipeline with Efficacious Drugs
    • OTC Analgesics Market to Witness Fastest Growth
    • Topical Analgesics Market Holds Significant Share
    • Combination Therapies Gain Prominence
    • A Few Novel Analgesic Products under Development
    • E-commerce Platforms Strengthen Pharmaceutical Distribution in Crisis Period
    • Neuropathic Pain Management: Market with High Potential
    • Migraine Market: A Core Vertical in CNS Pain Management
    • Migraine Care: Select Patent Expiries (2013-2015)
    • Reyvow, Eli Lilly's Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
    • Three New Migraine Drugs Obtain FDA Approval
    • Eli Lilly's Emgality Receives FDA Approval
    • Increasing Cases of Peripheral Nerve Injuries Drive the Analgesics Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Prescription by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Prescription by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Prescription by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for OTC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for OTC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for OTC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 21: World 16-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 24: World 16-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Transdermal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Transdermal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 27: World 16-Year Perspective for Transdermal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Rectal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Rectal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 30: World 16-Year Perspective for Rectal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 31: World Analgesics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 34: World 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
  • WORLD BRANDS

III. MARKET ANALYSIS

  • UNITED STATES
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • JAPAN
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • CHINA
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 64: China 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 67: China 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 70: China 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • EUROPE
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Analgesics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Analgesics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
  • FRANCE
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 85: France 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 88: France 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 91: France 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • GERMANY
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Analgesics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
  • AUSTRALIA
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • INDIA
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 169: India 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 172: India 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 175: India 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Analgesics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Analgesics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Analgesics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Analgesics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030
  • AFRICA
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2023 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2023 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2023 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!